![Le Journal des Biotechs](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=360&height=360&auto=webp)
Le Journal des Biotechs
Deux fois par mois, Boursorama et Ulysse Communication s'associent pour présenter toute l'actualité du secteur des biotechs (Genfit, AB Science, Onxeo...) et des medtechs (Stentys, Mauna Kea, Carmat) cotées en Bourse, avec un observateur privilégié du secteur. Ensuite, l'émission donnera la parole à un ou deux dirigeants de biotechs.
Une émission présentée par Laurent Grassin (rédacteur en chef de l'équipe média de Boursorama) et Pierre-Louis Germain (Consultant « Life Sciences » chez Ulysse Communication)
Business
Science
![Le Journal des Biotechs](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=64&height=64&auto=webp)
Episodes
129
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Aram Mangasarian, TME Pharma
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Pascal Prigent (Genfit)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Nicolas Poirier, (Ose Immunotherapeutics)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Gilles Avenard (Acticor), Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Laurent Levy (Nanobiotix), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Thibaut du Fayet (Phaxiam), Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Patrick Alexandre (Crossject)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Christophe Douat, Medincell
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Laurence Rodriguez (Gensight), Laura Roba (Degroof Petercam)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Gavin Spencer (Nicox)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Didier Laurens (Advicenne)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Olivier Soula (Adocia), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Jocelyne Bloch et Grégoire Courtine (Onward)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Pierre Josselin (Fermentalg), Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Pascal Ghoson (Oxurion)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Hervé Brailly (Innate)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Jean-Luc Vandebroek (Hyloris)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Nawal Ouzren (Sensorion), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Pascal Prigent (Genfit), Laura Roba (Degroof Petercam)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : André Choulika (Cellectis), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Marc de Garidel (Abivax)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Frédéric Cren (Inventiva), Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Sacha Loiseau (Mauna Kea), Aram Mangasarian (TME Pharma), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Olivier Soula (Adocia)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Bernard Gilly (Gensight), Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Gilles Avenard, Acticor Biotech
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Laurent Levy (Nanobiotix), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Aram Mangasarian (TME Pharma)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Pascal Prigent (Genfit)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Pier Vincenzo Piazza (Aelis Farma)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Nawal Ouzren (Sensorion), Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Sébastien Peltier (Valbiotis), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Mathieu Charvériat (Theranexus)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Nicolas Poirier (OSE), Mohamed Kaabouni (Portzamparc)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Christophe Douat, président de Medincell
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Sacha Loiseau (Mauna Kea), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Pascal Prigent (Genfit), Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des Biotechs : interview de Mondher Mahjoubi (Innate)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des Biotechs : interview de Hervé Affagard (Maat Pharma)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des Biotechs : Hervé Affagard (Maat Pharma), Mondher Mahjoubi (Innate Pharma)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Thomas Kuhn, directeur général de Poxel
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Alexia Rieger (BioSenic), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Didier Laurens (Advicenne), Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Cyrille Tupin (Abionyx), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Aram Mangasarian (TME Pharma), Sacha Pouget (Biomed Impact)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Eric Dessertenne, Directeur général de Biocorp
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Olivier Soula (Adocia), Sacha Pouget (Biomed Impact)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Maryvonne Hiance, présidente de HealthTech For Care
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Ludovic Lastennet (Implanet), Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Gilles Avenard, Acticor Biotech
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Pascal Prigent (Genfit), Frédéric Gomez (Pharmium Securites)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Christophe Douat (Medincell), Sacha Pouget (Kalliste Biotechs)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Philippe Genne, PDG d'Oncodesign
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Lloyd Diamond (Pixium Vision) & Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Didier Hoch, PDG de Pherecydes
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Nawal Ouzren (Sensorion), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Marc Delcourt (Global Bioenergies), Cédric Moreau (Sofinnova Partners)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Olivier Soula, directeur général délégué d'Adocia
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Fabrice Plasson (Amoéba) & Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Jean-Claude Maurel (Medesis), Shefali Agarwal (Onxeo)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Hervé Affagard (MaaT Pharma), Mohamed Kaabouni (Portzamparc)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Sébastien Peltier, président du directoire de Valbiotis
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Jean-Luc Vandebroek (Hyloris) Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Laurent Levy (Nanobiotix) & Sacha Pouget (Biotech Bourse)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : L'interview de Laurent Lévy (Nanobiotix)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Le point sur l'actualité avec Sacha Pouget (Biotech Bourse)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Hedi Ben Brahim (Transgene) & Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : L'interview de Hedi Ben Brahim (Transgene)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Le point sur l'actualité avec Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Le point d'actu avec Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : L'entretien de Didier Laurens (Advicienne)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Didier Laurens (Advicenne), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : L'entretien de Pascal Prigent, directeur général de Genfit
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : L' entretien de Pierre Dumouchel, PDG de Safe
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : L'entretien de Cédric Moreau (Sofinnova Partners)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Le point d'actu avec Sacha Pouget (Biotech Bourse)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Cédric Moreau (Sofinnova Partners), Sacha Pouget (Biotech Bourse)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Cyrille Tupin, directeur général d'Abionyx
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : L'entretien de Christophe Douat (Medincell)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Gilles Avenard (Acticor Biotech), Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : L'entretien de Gilles Avenard (Acticor Biotech) dans le JDB
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Mondher Mahjoubi (Innate Pharma), Sacha Pouget (Biotech Bourse)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Guy-Charles Fanneau de La Horie (Pherecydes)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Karen Aiach (Lysogene), Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Didier Laurens (Advicenne) & Sacha Pouget (Biotech Bourse)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Pascal Prigent, (DG de Genfit) & Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Marc Delcourt (Global Bioenergies) & Christophe Dombu (Portzamparc)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Robert Gershon (Mauna Kea) & Sacha Pouget (Biotech Bourse)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Stanislas Veillet (Biophytis) & Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Laurent Lévy (Nanobiotix) & Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Cédric Moreau (Sofinnova Partners) & Sacha Pouget (Biotech Bourse)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Pierre Dumouchel (Safe Orthopaedics) & Thomas Guillot (Degroof Petercam)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Pascal Prigent, DG de Genfit, Jamila El Bougrini, analyste (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : GC Fanneau de la Horie (Pherecydes) & S. Pouget (Kaliste Biotech Advisors)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Jean-Philippe Milon, directeur général de Quantum Genomics
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Pierre Moustial (Lauxera Capital Partners) & Martial Descoutures (Oddo BHF)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Judith Greciet, DG d'Onxeo, Frédéric Gomez, analyste biotech (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le point sur l'actualité du secteur avec Frédéric Gomez, analyste biotech chez Pharmium Securities
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
L'entretien de Judith Greciet : Directrice générale d'Onxeo
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Frédéric Cren, PDG d'Inventiva, Martial Descoutures, analyste biotech (Oddo BHF)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le point sur l'actualité avec Martial Descoutures (analyste pharma / biotech chez Oddo BHF)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
L'entretien de Frédéric Cren : PDG et cofondateur d'Inventiva
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Karen Aiach, PDG de Lysogene, Sacha Pouget (Kaliste Biotech Advisors)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le point sur l'actualité du secteur avec Sacha Pouget (Directeur associé chez Kaliste Biotechs Advisors)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
L'entretien de Karen Aiach : Fondatrice et PDG de Lysogene
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le JDB : Jean-Philippe Milon, directeur général de Quantum Genomics
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
L'entretien de David Solomon (Pharnext)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le point sur l'actualité du secteur avec Olivier Litzka (Andera Partners)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Bone Therapeutics : Miguel Forte détaille l'accord avec Link Health et Pregene
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Journal des biotechs : Martin Stephan (Carbios) & Jamila El Bougrini (Invest Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le journal des biotechs : Franck Grimaud (Valneva) & Frédéric Gomez (Pharmium Securities)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
L'interview de Laurent Levy, président du directoire de Nanobiotix.
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Point d'actu : Sébastien Malafosse, analyste pharma-biotechs chez Oddo BHF
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des biotechs : Michele Garufi, PDG de Nicox, François Miceli, Sofimac Innovation
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Interview de Pierre Dumouchel, PDG de Safe Orthopaedics
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Point d'actu : Gilles Nobécourt, associé chez Andera Partners
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Pascal Prigent, directeur général de Genfit revient sur les résultats d'Elafibranor dans la Nash
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Entretien avec Sébastien Peltier de Valbiotis
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Point d'actu avec Christophe Dombu, analyste Pharma / Biotech chez Portzamparc
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Biocorp : Eric Dessertenne revient sur les résultats 2019
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Stanislas Veillet, PDG de Biophytis & Cédric Moreau (Sofinnova Partners)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Theranexus : Franck Mouthon détaille les résultats de phase II dans Parkinson
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Interview de Daniel Cohen, directeur général de Pharnext
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
L'analyse de Jamila El Bougrini (Gilbert Dupont)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Interview de Stéphane Altaba, COO de Genomic Vision
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Interview de Alain Moussy, directeur général d'AB Science
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des Biotechs : l'analyse de Martial Descoutures (Oddo BHF)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)
Le Journal des Biotechs : Entretien de Laurent Levy (Nanobiotix)
![episode artwork](https://artworks.360.audion.fm/73e65eaa-fc50-4bad-bb22-2e0ab786a94a.jpg?width=156&height=156&auto=webp)